Gain of 1q21 in multiple myeloma: From bad to worse?

Blood

Volumn 108, Issue 5, 2006, Pages 1426-1427

  Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3;

CANCER GROWTH; CHROMOSOME 13; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENOME; HUMAN; MULTIPLE MYELOMA; NOTE; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33748171974     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-06-028530     Document Type: Note

References (5)

1. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569-4575.
2. Walker BA, Leone PE, Jenner MW, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms and genes important in the pathogenesis of multiple myeloma. Blood. Prepublished on May 16, 2006, as DOI 10.1182/blood-2006-02-005496.
3. Gregory SG, Barlow KF, McLay KE, et al. The DNA sequence and biological annotation of human chromosome 1. Nature. 2006;441:315-321.
4. Avet Loiseau H, Attal M, Moreau P, et al. A comprehensive analysis of cytogenetic abnormalities in myeloma: results of the FISH analysis of 1000 patients enrolled in the IFM99 trials [abstract]. Blood. 2005;106. Abstract 622.
5. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005;10(suppl 1):117-126.